483 related articles for article (PubMed ID: 32172407)
1. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.
Yu J; Lal L; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
Support Care Cancer; 2020 Nov; 28(11):5491-5499. PubMed ID: 32172407
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis.
Yu J; Lal LS; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
Curr Med Res Opin; 2021 May; 37(5):755-759. PubMed ID: 33615925
[TBL] [Abstract][Full Text] [Related]
3. Inpatient Healthcare Resource Utilization, Costs, and Mortality in Adult Patients with Acute Graft-versus-Host Disease, Including Steroid-Refractory or High-Risk Disease, following Allogeneic Hematopoietic Cell Transplantation.
Yu J; Judy JT; Parasuraman S; Sinha M; Weisdorf D
Biol Blood Marrow Transplant; 2020 Mar; 26(3):600-605. PubMed ID: 31678539
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Increased Health Care Utilization and Costs during Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndromes in Adolescents and Young Adults Compared with Children: A Multicenter Study.
Rangarajan HG; Smith LC; Stanek JR; Hall M; Abu-Arja R; Auletta JJ; O'Brien SH
Biol Blood Marrow Transplant; 2019 May; 25(5):1031-1038. PubMed ID: 30625391
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis.
Bachier CR; Aggarwal SK; Hennegan K; Milgroom A; Francis K; Dehipawala S; Rotta M
Transplant Cell Ther; 2021 Jun; 27(6):504.e1-504.e6. PubMed ID: 34158154
[TBL] [Abstract][Full Text] [Related]
7. Healthcare Resource Utilization and Costs of Steroid-Associated Complications in Patients With Graft-Versus-Host Disease.
Bell EJ; Yu J; Bhatt V; Bunner SH; Lal LS; Galvin J; Weisdorf D
Transplant Cell Ther; 2022 Oct; 28(10):707.e1-707.e7. PubMed ID: 35483620
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
9. Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants.
Watson C; Xu H; Princic N; Sruti I; Barlev A
J Med Econ; 2020 Oct; 23(10):1159-1167. PubMed ID: 32643493
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes and Healthcare Resource Utilization for Gastrointestinal Acute Graft-versus-Host Disease after Allogeneic Transplantation for Hematologic Malignancy: A Retrospective US Administrative Claims Database Analysis.
Johnson BH; Taylor A; Kim G; Drahos J; Yang J; Akbari M; Shah NN
Biol Blood Marrow Transplant; 2019 Apr; 25(4):834-841. PubMed ID: 30625389
[TBL] [Abstract][Full Text] [Related]
11. Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States.
McGuirk J; Divine C; Moon SH; Chandak A; Zhang Z; Papanicolaou GA
Transplant Cell Ther; 2021 Jun; 27(6):505.e1-505.e9. PubMed ID: 33775616
[TBL] [Abstract][Full Text] [Related]
12. Severity of Acute Graft-versus-Host Disease and Associated Healthcare Resource Utilization, Cost, and Outcomes.
Farhadfar N; Leather HL; Wang S; Burton N; IrizarryGatell V; Itzler R; Salloum RG; Wingard JR
Transplant Cell Ther; 2021 Dec; 27(12):1007.e1-1007.e8. PubMed ID: 34537422
[TBL] [Abstract][Full Text] [Related]
13. Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation.
Yu J; Parasuraman S; Shah A; Weisdorf D
Curr Med Res Opin; 2019 Jun; 35(6):983-988. PubMed ID: 30461314
[TBL] [Abstract][Full Text] [Related]
14. Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient.
Maziarz RT; Devine S; Garrison LP; Agodoa I; Badaracco J; Gitlin M; Perales MA
Transplant Cell Ther; 2023 Oct; 29(10):637.e1-637.e9. PubMed ID: 37364775
[TBL] [Abstract][Full Text] [Related]
15. Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease.
Miller HK; Braun TM; Stillwell T; Harris AC; Choi S; Connelly J; Couriel D; Goldstein S; Kitko CL; Magenau J; Pawarode A; Reddy P; Riwes M; Yanik GA; Levine JE
Biol Blood Marrow Transplant; 2017 Mar; 23(3):522-528. PubMed ID: 28017733
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.
Cheng WY; Avery RK; Thompson-Leduc P; Cheung HC; Bo T; Duh MS; Hirji I
J Med Econ; 2022; 25(1):367-380. PubMed ID: 35240904
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.
Ramalingam S; Siamakpour-Reihani S; Bohannan L; Ren Y; Sibley A; Sheng J; Ma L; Nixon AB; Lyu J; Parker DC; Bain J; Muehlbauer M; Ilkayeva O; Kraus VB; Huebner JL; Spitzer T; Brown J; Peled JU; van den Brink M; Gomes A; Choi T; Gasparetto C; Horwitz M; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Sung AD
PLoS One; 2021; 16(6):e0252995. PubMed ID: 34170918
[TBL] [Abstract][Full Text] [Related]
18. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
El-Jawahri A; Chen YB; Brazauskas R; He N; Lee SJ; Knight JM; Majhail N; Buchbinder D; Schears RM; Wirk BM; Wood WA; Ahmed I; Aljurf M; Szer J; Beattie SM; Battiwalla M; Dandoy C; Diaz MA; D'Souza A; Freytes CO; Gajewski J; Gergis U; Hashmi SK; Jakubowski A; Kamble RT; Kindwall-Keller T; Lazarus HM; Malone AK; Marks DI; Meehan K; Savani BN; Olsson RF; Rizzieri D; Steinberg A; Speckhart D; Szwajcer D; Schoemans H; Seo S; Ustun C; Atsuta Y; Dalal J; Sales-Bonfim C; Khera N; Hahn T; Saber W
Cancer; 2017 May; 123(10):1828-1838. PubMed ID: 28102896
[TBL] [Abstract][Full Text] [Related]
19. Impact of cytomegalovirus complications on resource utilization and costs following hematopoietic stem cell transplant.
Schelfhout J; Bonafede M; Cappell K; Cole AL; Manjelievskaia J; Raval AD
Curr Med Res Opin; 2020 Jan; 36(1):33-41. PubMed ID: 31490093
[No Abstract] [Full Text] [Related]
20. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.
Guru Murthy GS; Hari PN; Szabo A; Pasquini M; Narra R; Khan M; Abedin S; Chhabra S; Dhakal B; D'Souza A; Drobyski WR; Rizzo JD; Runaas L; Shah NN; Shaw B; Saber W; Fenske T; Hamadani M
Biol Blood Marrow Transplant; 2019 Apr; 25(4):827-833. PubMed ID: 30572109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
